Literature DB >> 16417570

Modifications of the iron-neuromelanin system in Parkinson's disease.

Mauro Fasano1, Bruno Bergamasco, Leonardo Lopiano.   

Abstract

Parkinson's disease is a common neurodegenerative disorder with a mainly sporadic aetiology, although a number of monogenic familiar forms are known. Most of the motor symptoms are due to selective depletion of dopaminergic, neuromelanin-containing neurones of the substantia nigra pars compacta. Neuromelanin is the dark insoluble macromolecule that confers the black (substantia nigra) or grey (locus coeruleus) colour to monoaminergic basal ganglia. In particular, nigral neurones are pigmented because of the accumulation of by-products of oxidative metabolism of the neurotransmitter dopamine. The occurrence of dopamine (and all the enzymatic machinery required for dopamine synthesis, re-uptake and disposal) and neuromelanin, and a large amount of iron ions that interact with them, makes dopaminergic nigral neurones peculiarly susceptible to oxidative stress conditions that, in turn, may become amplified by the iron-neuromelanin system itself. In this mini-review we describe biophysical evidence for iron-neuromelanin modifications that support this hypothesis. Furthermore, we discuss the formation of the covalent linkage between alpha-synuclein and neuromelanin from the early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417570     DOI: 10.1111/j.1471-4159.2005.03638.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

2.  Encapsulation of a reactive core in neuromelanin.

Authors:  Shosuke Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

3.  Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach.

Authors:  Florian Tribl; Esther Asan; Thomas Arzberger; Thomas Tatschner; Elmar Langenfeld; Helmut E Meyer; Gerhard Bringmann; Peter Riederer; Manfred Gerlach; Katrin Marcus
Journal:  Mol Cell Proteomics       Date:  2009-03-24       Impact factor: 5.911

Review 4.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 5.  Accumulation of nuclear DNA damage or neuron loss: molecular basis for a new approach to understanding selective neuronal vulnerability in neurodegenerative diseases.

Authors:  Ivona Brasnjevic; Patrick R Hof; Harry W M Steinbusch; Christoph Schmitz
Journal:  DNA Repair (Amst)       Date:  2008-05-23

6.  Bacterial melanin increases electrical activity of neurons in Substantia Nigra pars compacta.

Authors:  T R Petrosyan; V A Chavushyan; A S Hovsepyan
Journal:  J Neural Transm (Vienna)       Date:  2014       Impact factor: 3.575

Review 7.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.